DOCSLIB.ORG

Post-Transcriptional Regulation of Aortic Calcification in KLOTHO Deficient Mice: Impact Of

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Post-Transcriptional Regulation of Aortic Calcification in KLOTHO Deficient Mice: Impact Of Post-transcriptional regulation of aortic calcification in KLOTHO deficient mice: impact of miR-145 and miR-378 Ying Tang1, *, Tapan A. Shah1, *, †, Edward J. Yurkow2, and Melissa B. Rogers1, ‡ Fig. S1. KEGG (Kyoto Encyclopedia of Genes and Genomes) analyses of differentially expressed miRNAs in male Klotho homozygous mutant mice. Fig. S2. KEGG (Kyoto Encyclopedia of Genes and Genomes) analyses of differentially expressed miRNAs in female Klotho homozygous mutant mice. Fig. S3. Gene Ontology (GO) analyses of differentially expressed miRNAs in male Klotho homozygous mutant mice. Fig. S4. Gene Ontology (GO) analyses of differentially expressed miRNAs in female Klotho homozygous mutant mice. Fig. S5. Interaction network of miRNAs down-regulated in male Klotho homozygotes relative to healthy controls. Fig. S6. Interaction network of miRNAs down-regulated in female Klotho homozygotes relative to healthy controls. Fig. S7. Experimental Controls. Table S1. Average miRNA abundance in aorta from Klotho mutant homozygotes relative to healthy control (p<0.05). Table S2. Genes targeted by selected miRNAs that may influence aortic calcification. Table S3. Known modulators of BMP signaling. Table S4. Klotho wild type and Klotho heterozygous mice are equivalent controls Tang et al. Supporting Information, MicroRNA profiles in calcified vs. healthy aorta S2 Legend on next page Tang et al. Supporting Information, MicroRNA profiles in calcified vs. healthy aorta Fig. S1. KEGG (Kyoto Encyclopedia of Genes and Genomes) analyses of differentially expressed miRNAs in male Klotho homozygous mutant mice. The genes potentially targeted by up (A) or down-regulated (B) miRNAs were predicted by DIANA TOOLS. Target genes were grouped into gene pathways using the KEGG database. The y-axis represents the name of the KEGG pathway, and the x-axis represents the number of the genes in a certain pathway. Low p adjust values are in red and high p adjust values are in blue. KEGG pathways that are directly related to the osteogenic differentiation that occurs in vascular calcification are marked with an asterisk (*). S3 Tang et al. Supporting Information, MicroRNA profiles in calcified vs. healthy aorta S4 Legend on next page Tang et al. Supporting Information, MicroRNA profiles in calcified vs. healthy aorta Fig. S2. KEGG (Kyoto Encyclopedia of Genes and Genomes) analyses of differentially expressed miRNAs in female Klotho homozygous mutant mice. The genes potentially targeted by up (A) or down-regulated (B) miRNAs were predicted by DIANA TOOLS. Target genes were grouped into gene pathways using the KEGG database. The y-axis represents the name of the KEGG pathway, and the x-axis represents the number of the genes in a certain pathway. Low p adjust values are in red and high p adjust values are in blue. KEGG pathways that are directly related to the osteogenic differentiation that occurs in vascular calcification are marked with an asterisk (*). S5 Tang et al. Supporting Information, MicroRNA profiles in calcified vs. healthy aorta S6 Legend on next page Tang et al. Supporting Information, MicroRNA profiles in calcified vs. healthy aorta Fig. S3. Gene Ontology (GO) analyses of differentially expressed miRNAs in male Klotho homozygous mutant mice. The genes potentially targeted by up-regulated (A) or down-regulated (B) miRNAs were predicted by DIANA TOOLS. Target genes were grouped into GO molecular function terms using the GO database. The y-axis represents the name of the GO molecular function term, and the x-axis represents the number of genes associated with each GO molecular function term. Low p adjust values are in red and high p adjust values are in blue. S7 Tang et al. Supporting Information, MicroRNA profiles in calcified vs. healthy aorta S8 Legend on next page Tang et al. Supporting Information, MicroRNA profiles in calcified vs. healthy aorta Fig. S4. Gene Ontology (GO) analyses of differentially expressed miRNAs in female Klotho homozygous mutant mice. The genes potentially targeted by up- regulated (A) or down-regulated (B) miRNAs were predicted by DIANA TOOLS. Target genes were grouped into GO molecular function terms using the GO database. The y- axis represents the name of the GO molecular function term, and the x-axis represents the number of genes associated with each GO molecular function term. Low p adjust values are in red and high p adjust values are in blue. S9 Tang et al. Supporting Information, MicroRNA profiles in calcified vs. healthy aorta Fig. S5. Interaction network of miRNAs down-regulated in male Klotho homozygotes relative to healthy controls. These miRNAs were down-regulated in diseased Klotho male homozygotes according to microarray measurements and are predicted to target Bmp2 and/or the downstream BMP signaling intermediaries, Smads1, 5, 9. The subset of miRNAs whose abundance decreased in both male and female Klotho homozygotes are in bold. S10 Tang et al. Supporting Information, MicroRNA profiles in calcified vs. healthy aorta Fig. S6. Interaction network of miRNAs down-regulated in female Klotho homozygotes relative to healthy controls. These miRNAs were down-regulated in diseased Klotho female homozygotes according to microarray measurements and are predicted to target Bmp2 and/or the downstream BMP signaling intermediaries, Smads1, 5, 9. The subset of miRNAs whose abundance decreased in both male and female Klotho homozygotes are in bold. S11 Tang et al. Supporting Information, MicroRNA profiles in calcified vs. healthy aorta Fig. S7. Experimental Controls. A, B. Grinding tissue with glass beads does not significantly affect calcium or protein yield. Whole aorta was ground in liquid nitrogen either with or without glass beads. Frozen ground powder tissue was split two ways for protein and calcium assays. A. Effect of glass beads on calcium, protein and pSMAD1/5/9 levels. Duplicate measurements are presented with range. Experiments were repeated twice with similar results. B. Representative blots showing pSMAD1/5/9, actin levels and the Ponceau S stained membrane after transfer. The positive control lane (+ Ctrl) was loaded with lysate from MC3T3-E1 cells transfected with a Bmp2 expression plasmid. C, D. Validation of the phospho-SMAD1/5/9 antibody. MC3T3-E1 (C) and C3H10T1/2 (D) cells were transfected with an expression plasmid encoding BMP2 (B2) or luciferase (Luc) (1). Cells were then lysed in RIPA buffer and subjected to western blotting as described in the experimental procedures section. These representative blots show that pSMAD1/5/9 levels were induced in cells transfected with the Bmp2 expressing plasmid relative to the luciferase plasmid. Actin levels and a Ponceau S stained membrane are shown as loading controls. S12 Tang et al. Supporting Information, MicroRNA profiles in calcified vs. healthy aorta Table S1. Average miRNA abundance in aorta from Klotho mutant homozygotes relative to healthy control (p<0.05). Raw data is available in the Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/, GSE135759). % Male control Female % control mmu-miR-16-1-3p 1344 mmu-miR-205-5p 15398 mmu-miR-711 1338 mmu-miR-429-3p 2226 mmu-miR-5620-3p 687 mmu-miR-16-1-3p 1331 mmu-miR-466f 630 mmu-miR-141-3p 1061 mmu-miR-466j 585 mmu-miR-205-3p 581 mmu-miR-669m-5p 532 mmu-miR-6359 581 mmu-miR-466m-5p 532 mmu-miR-200a-5p 563 mmu-miR-669b-5p 491 mmu-miR-675-3p 543 mmu-miR-466f-5p 489 mmu-miR-466f-5p 540 mmu-miR-669o-5p 473 mmu-miR-296-3p 507 mmu-miR-195a-3p 470 mmu-miR-1946b 450 mmu-miR-7030-5p 466 mmu-let-7f-1-3p 438 mmu-miR-466h-5p 465 mmu-miR-1947-3p 427 mmu-miR-665-5p 433 mmu-miR-291b-5p 386 mmu-miR-3082-5p 432 mmu-miR-6241 383 mmu-miR-669k-5p 415 mmu-miR-3092-3p 366 mmu-miR-696 415 mmu-miR-6546-3p 350 mmu-miR-467h 414 mmu-miR-183-3p 339 mmu-miR-7654-3p 405 mmu-miR-1946a 333 mmu-miR-669l-5p 398 mmu-miR-669k-5p 331 mmu-miR-8119 378 mmu-miR-18a-3p 316 mmu-miR-5620-5p 369 mmu-miR-1930-3p 312 mmu-miR-669f-5p 366 mmu-miR-489-3p 302 mmu-miR-714 360 mmu-miR-376a-3p 296 mmu-miR-6968-5p 328 mmu-miR-744-5p 294 mmu-miR-2137 327 mmu-miR-539-5p 274 mmu-miR-5130 321 mmu-miR-7047-3p 274 mmu-miR-7023-5p 295 mmu-miR-7049-5p 273 mmu-miR-7016-5p 286 mmu-miR-7079-5p 265 mmu-miR-92b-5p 286 mmu-miR-181c-3p 263 mmu-miR-3547-5p 278 mmu-miR-381-5p 263 mmu-miR-146b-5p 278 mmu-miR-7004-5p 249 mmu-miR-7033-5p 271 mmu-miR-191-3p 246 mmu-miR-6980-5p 271 mmu-let-7b-3p 242 mmu-miR-297a-5p 265 mmu-miR-141-5p 234 mmu-miR-669e-5p 245 mmu-miR-7684-3p 231 S13 Tang et al. Supporting Information, MicroRNA profiles in calcified vs. healthy aorta mmu-miR-669a-5p 243 mmu-miR-7241-5p 227 mmu-miR-669p-5p 243 mmu-miR-5129-3p 227 mmu-miR-7648-3p 237 mmu-miR-6958-5p 225 mmu-miR-1982-5p 236 mmu-miR-7684-5p 223 mmu-miR-15a-3p 224 mmu-miR-203-5p 223 mmu-miR-6971-5p 223 mmu-miR-7669-3p 220 mmu-miR-7005-5p 221 mmu-miR-383-5p 215 mmu-miR-762 220 mmu-miR-7082-3p 209 mmu-miR-7083-5p 220 mmu-miR-17-5p 205 mmu-miR-6912-5p 217 mmu-miR-7682-3p 200 mmu-miR-466c-5p 215 mmu-miR-704 198 mmu-miR-6909-5p 215 mmu-miR-702-3p 197 mmu-miR-574-5p 213 mmu-miR-468-3p 195 mmu-miR-669d-5p 212 mmu-miR-92a-1-5p 194 mmu-miR-1892 209 mmu-miR-8103 191 mmu-miR-1224-5p 209 mmu-miR-7077-5p 188 mmu-miR-7085-5p 208 mmu-miR-7008-5p 186 mmu-miR-346-3p 208 mmu-let-7i-3p 183 mmu-miR-5119 204 mmu-miR-450b-5p 180 mmu-miR-7686-5p 201 mmu-miR-200c-5p 179 mmu-miR-7036-5p 201 mmu-miR-673-3p 176 mmu-miR-6921-5p 197 mmu-miR-6929-3p 167 mmu-miR-6349 197 mmu-miR-3098-5p 167 mmu-miR-8095 195 mmu-miR-7057-3p 167 mmu-miR-7048-5p 194 mmu-miR-18b-5p 163 mmu-miR-21a-5p 193 mmu-miR-1983 159 mmu-miR-1894-3p 192 mmu-miR-7074-3p 159 mmu-miR-6391 189 mmu-miR-465a-5p 157 mmu-miR-7684-3p 185 mmu-miR-3109-5p 157 mmu-miR-1187 184 mmu-miR-146b-3p 156 mmu-miR-7042-5p 184 mmu-miR-147-3p 156 mmu-miR-6240 183 mmu-miR-297c-5p 154 mmu-miR-3470a 181 mmu-miR-7054-5p 153 mmu-miR-7011-5p 176 mmu-miR-7115-3p 150 mmu-miR-7235-5p 174 mmu-miR-7007-3p 149 mmu-miR-5100 173 mmu-miR-6959-5p 148 mmu-miR-8101 171 mmu-miR-7225-3p 147 mmu-miR-744-5p 171 mmu-miR-7080-3p 145 mmu-miR-6991-5p 169 mmu-miR-1930-5p 143 mmu-miR-7069-5p 169 mmu-miR-743a-5p 142 mmu-miR-6935-5p 168 mmu-miR-292-3p 142 S14 Tang et al.
Load more

Recommended publications
  • Characterization of Pulmonary Arteriovenous Malformations in ACVRL1 Versus ENG Mutation Carriers in Hereditary Hemorrhagic Telangiectasia
    © American College of Medical Genetics and Genomics ORIGINAL RESEARCH ARTICLE Characterization of pulmonary arteriovenous malformations in ACVRL1 versus ENG mutation carriers in hereditary hemorrhagic telangiectasia Weiyi Mu, ScM1, Zachary A. Cordner, MD, PhD2, Kevin Yuqi Wang, MD3, Kate Reed, MPH, ScM4, Gina Robinson, RN5, Sally Mitchell, MD5 and Doris Lin, MD, PhD5 Purpose: Pulmonary arteriovenous malformations (pAVMs) are mutation carriers to have pAVMs (P o 0.001) or multiple lesions major contributors to morbidity and mortality in hereditary (P = 0.03), and to undergo procedural intervention (P = 0.02). hemorrhagic telangiectasia (HHT). Mutations in ENG and ACVRL1 Additionally, pAVMs in ENG carriers were more likely to exhibit underlie the vast majority of clinically diagnosed cases. The aims of bilateral lung involvement and growth over time, although this did this study were to characterize and compare the clinical and not reach statistical significance. The HHT severity score was morphologic features of pAVMs between these two genotype significantly higher in ENG than in ACVRL1 (P = 0.02). groups. Conclusion: The propensity and multiplicity of ENG-associated Methods: Sixty-six patients with HHT and affected family pAVMs may contribute to the higher disease severity in this members were included. Genotype, phenotypic data, and imaging genotype, as reflected by the HHT severity score and the frequency were obtained from medical records. Morphologic features of of interventional procedures. pAVMs were analyzed using computed tomography angiography. Genet Med HHT symptoms, pAVM imaging characteristics, frequency of advance online publication 19 October 2017 procedural intervention, and HHT severity scores were compared Key Words: ACVRL1; ENG; genotype-phenotype correlation; between ENG and ACVRL1 genotype groups.
    [Show full text]
  • Tumor Promoting Effect of BMP Signaling in Endometrial Cancer
    International Journal of Molecular Sciences Article Tumor Promoting Effect of BMP Signaling in Endometrial Cancer Tomohiko Fukuda 1,* , Risa Fukuda 1, Kohei Miyazono 1,2,† and Carl-Henrik Heldin 1,*,† 1 Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Box 582, Uppsala University, SE-751 23 Uppsala, Sweden; [email protected] (R.F.); [email protected] (K.M.) 2 Department of Molecular Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan * Correspondence: [email protected] (T.F.); [email protected] (C.-H.H.); Tel.: +46-18-4714738 (T.F.); +46-18-4714738 (C.-H.H.) † These authors contributed equally to this work. Abstract: The effects of bone morphogenetic proteins (BMPs), members of the transforming growth factor-β (TGF-β) family, in endometrial cancer (EC) have yet to be determined. In this study, we analyzed the TCGA and MSK-IMPACT datasets and investigated the effects of BMP2 and of TWSG1, a BMP antagonist, on Ishikawa EC cells. Frequent ACVR1 mutations and high mRNA expressions of BMP ligands and receptors were observed in EC patients of the TCGA and MSK-IMPACT datasets. Ishikawa cells secreted higher amounts of BMP2 compared with ovarian cancer cell lines. Exogenous BMP2 stimulation enhanced EC cell sphere formation via c-KIT induction. BMP2 also induced EMT of EC cells, and promoted migration by induction of SLUG. The BMP receptor kinase inhibitor LDN193189 augmented the growth inhibitory effects of carboplatin. Analyses of mRNAs of several BMP antagonists revealed that TWSG1 mRNA was abundantly expressed in Ishikawa cells.
    [Show full text]
  • Molecular Classification of Patients with Unexplained Hamartomatous and Hyperplastic Polyposis
    ORIGINAL CONTRIBUTION Molecular Classification of Patients With Unexplained Hamartomatous and Hyperplastic Polyposis Kevin Sweet, MS, CGC Context Significant proportions of patients with hamartomatous polyposis or with Joseph Willis, MD hyperplastic/mixed polyposis remain without specific clinical and molecular diagnosis Xiao-Ping Zhou, MD, PhD or present atypically. Assigning a syndromic diagnosis is important because it guides management, especially surveillance and prophylactic surgery. Carol Gallione, PhD Objective To systematically classify patients with unexplained hamartomatous or hy- Takeshi Sawada, MD, PhD perplastic/mixed polyposis by extensive molecular analysis in the context of central Pia Alhopuro, MD rereview of histopathology results. Sok Kean Khoo, PhD Design, Setting, and Patients Prospective, referral-based study of 49 unrelated patients from outside institutions (n=28) and at a comprehensive cancer center (n=21), Attila Patocs, MD, PhD conducted from May 2, 2002, until December 15, 2004. Germline analysis of PTEN, Cossette Martin, PhD BMPR1A, STK11 (sequence, deletion), SMAD4, and ENG (sequence), specific exon screen- Scott Bridgeman, BSc ing of BRAF, MYH, and BHD, and rereview of polyp histology results were performed. John Heinz, PhD Main Outcome Measures Molecular, clinical, and histopathological findings in pa- tients with unexplained polyposis. Robert Pilarski, MS, CGC Results Of the 49 patients, 11 (22%) had germline mutations. Of 14 patients with Rainer Lehtonen, BSc juvenile polyposis, 2 with early-onset disease had mutations in ENG, encoding endo- Thomas W. Prior, PhD glin, previously only associated with hereditary hemorrhagic telangiectasia; 1 had hemi- zygous deletion encompassing PTEN and BMPR1A; and 1 had an SMAD4 mutation. Thierry Frebourg, MD, PhD One individual previously classified with Peutz-Jeghers syndrome had a PTEN dele- Bin Tean Teh, MD, PhD tion.
    [Show full text]
  • FOP) Can Be Rescued by the Drug Candidate Saracatinib
    Stem Cell Reviews and Reports https://doi.org/10.1007/s12015-020-10103-9 ActivinA Induced SMAD1/5 Signaling in an iPSC Derived EC Model of Fibrodysplasia Ossificans Progressiva (FOP) Can Be Rescued by the Drug Candidate Saracatinib Susanne Hildebrandt1,2,3 & Branka Kampfrath1 & Kristin Fischer3,4 & Laura Hildebrand2,3 & Julia Haupt1 & Harald Stachelscheid3,4 & Petra Knaus 1,2 Accepted: 1 December 2020 # The Author(s) 2021 Abstract Balanced signal transduction is crucial in tissue patterning, particularly in the vasculature. Heterotopic ossification (HO) is tightly linked to vascularization with increased vessel number in hereditary forms of HO, such as Fibrodysplasia ossificans progressiva (FOP). FOP is caused by mutations in the BMP type I receptor ACVR1 leading to aberrant SMAD1/5 signaling in response to ActivinA. Whether observed vascular phenotype in human FOP lesions is connected to aberrant ActivinA signaling is unknown. Blocking of ActivinA prevents HO in FOP mice indicating a central role of the ligand in FOP. Here, we established a new FOP endothelial cell model generated from induced pluripotent stem cells (iECs) to study ActivinA signaling. FOP iECs recapitulate pathogenic ActivinA/SMAD1/5 signaling. Whole transcriptome analysis identified ActivinA mediated activation of the BMP/ NOTCH pathway exclusively in FOP iECs, which was rescued to WT transcriptional levels by the drug candidate Saracatinib. We propose that ActivinA causes transcriptional pre-patterning of the FOP endothelium, which might contribute to differential vascularity in FOP lesions compared to non-hereditary HO. Keywords FOP . BMP-receptor . Activin . iPSCs . Human endothelial cells . HO . Saracatinib Introduction pathological conditions such as cancer and chronic inflamma- tion [2].
    [Show full text]
  • Arteriovenous Malformations—Current Understanding of the Pathogenesis with Implications for Treatment
    International Journal of Molecular Sciences Review Arteriovenous Malformations—Current Understanding of the Pathogenesis with Implications for Treatment Katharina Schimmel 1,2 , Md Khadem Ali 1,2 , Serena Y. Tan 3 , Joyce Teng 4, Huy M. Do 5,6, Gary K. Steinberg 6, David A. Stevenson 7 and Edda Spiekerkoetter 1,2,* 1 Division Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Stanford University, Stanford, CA 94305, USA; [email protected] (K.S.); [email protected] (M.K.A.) 2 Vera Moulton Wall Center for Pulmonary Vascular Disease, Stanford University, Stanford, CA 94305, USA 3 Department of Pathology, Stanford University, Stanford, CA 94305, USA; [email protected] 4 Department of Dermatology, Lucile Packard Children’s Hospital, Stanford University, Stanford, CA 94305, USA; [email protected] 5 Department of Radiology (Neuroimaging and Neurointervention), Stanford University, Stanford, CA 94305, USA; [email protected] 6 Department of Neurosurgery and Stanford Stroke Center, Stanford University, Stanford, CA 94305, USA; [email protected] 7 Department of Pediatrics, Division of Medical Genetics, Stanford University, Stanford, CA 94305, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-(650)-739-5031 Abstract: Arteriovenous malformations are a vascular anomaly typically present at birth, charac- terized by an abnormal connection between an artery and a vein (bypassing the capillaries). These Citation: Schimmel, K.; Ali, M.K.; high flow lesions can vary in size and location. Therapeutic approaches are limited, and AVMs Tan, S.Y.; Teng, J.; Do, H.M.; Steinberg, can cause significant morbidity and mortality. Here, we describe our current understanding of the G.K.; Stevenson, D.A.; Spiekerkoetter, pathogenesis of arteriovenous malformations based on preclinical and clinical findings.
    [Show full text]
  • PRODUCTS and SERVICES Target List
    PRODUCTS AND SERVICES Target list Kinase Products P.1-11 Kinase Products Biochemical Assays P.12 "QuickScout Screening Assist™ Kits" Kinase Protein Assay Kits P.13 "QuickScout Custom Profiling & Panel Profiling Series" Targets P.14 "QuickScout Custom Profiling Series" Preincubation Targets Cell-Based Assays P.15 NanoBRET™ TE Intracellular Kinase Cell-Based Assay Service Targets P.16 Tyrosine Kinase Ba/F3 Cell-Based Assay Service Targets P.17 Kinase HEK293 Cell-Based Assay Service ～ClariCELL™ ～ Targets P.18 Detection of Protein-Protein Interactions ～ProbeX™～ Stable Cell Lines Crystallization Services P.19 FastLane™ Structures ～Premium～ P.20-21 FastLane™ Structures ～Standard～ Kinase Products For details of products, please see "PRODUCTS AND SERVICES" on page 1～3. Tyrosine Kinases Note: Please contact us for availability or further information. Information may be changed without notice. Expression Protein Kinase Tag Carna Product Name Catalog No. Construct Sequence Accession Number Tag Location System HIS ABL(ABL1) 08-001 Full-length 2-1130 NP_005148.2 N-terminal His Insect (sf21) ABL(ABL1) BTN BTN-ABL(ABL1) 08-401-20N Full-length 2-1130 NP_005148.2 N-terminal DYKDDDDK Insect (sf21) ABL(ABL1) [E255K] HIS ABL(ABL1)[E255K] 08-094 Full-length 2-1130 NP_005148.2 N-terminal His Insect (sf21) HIS ABL(ABL1)[T315I] 08-093 Full-length 2-1130 NP_005148.2 N-terminal His Insect (sf21) ABL(ABL1) [T315I] BTN BTN-ABL(ABL1)[T315I] 08-493-20N Full-length 2-1130 NP_005148.2 N-terminal DYKDDDDK Insect (sf21) ACK(TNK2) GST ACK(TNK2) 08-196 Catalytic domain
    [Show full text]
  • Cardiovascular Diseases Genetic Testing Program Information
    Cardiovascular Diseases Genetic Testing Program Description: Congenital Heart Disease Panels We offer comprehensive gene panels designed to • Congenital Heart Disease Panel (187 genes) diagnose the most common genetic causes of hereditary • Heterotaxy Panel (114 genes) cardiovascular diseases. Testing is available for congenital • RASopathy/Noonan Spectrum Disorders Panel heart malformation, cardiomyopathy, arrythmia, thoracic (31 genes) aortic aneurysm, pulmonary arterial hypertension, Marfan Other Panels syndrome, and RASopathy/Noonan spectrum disorders. • Pulmonary Arterial Hypertension (PAH) Panel Hereditary cardiovascular disease is caused by variants in (20 genes) many different genes, and may be inherited in an autosomal dominant, autosomal recessive, or X-linked manner. Other Indications: than condition-specific panels, we also offer single gene Panels: sequencing for any gene on the panels, targeted variant • Confirmation of genetic diagnosis in a patient with analysis, and targeted deletion/duplication analysis. a clinical diagnosis of cardiovascular disease Tests Offered: • Carrier or pre-symptomatic diagnosis identification Arrythmia Panels in individuals with a family history of cardiovascular • Comprehensive Arrhythmia Panel (81 genes) disease of unknown genetic basis • Atrial Fibrillation (A Fib) Panel (28 genes) Gene Specific Sequencing: • Atrioventricular Block (AV Block) Panel (7 genes) • Confirmation of genetic diagnosis in a patient with • Brugada Syndrome Panel (21 genes) cardiovascular disease and in whom a specific
    [Show full text]
  • Pulmonary Vascular Complications in Hereditary Hemorrhagic Telangiectasia and the Underlying Pathophysiology
    International Journal of Molecular Sciences Review Pulmonary Vascular Complications in Hereditary Hemorrhagic Telangiectasia and the Underlying Pathophysiology Sala Bofarid 1, Anna E. Hosman 2, Johannes J. Mager 2, Repke J. Snijder 2 and Marco C. Post 1,3,* 1 Department of Cardiology, St. Antonius Hospital, 3435 CM Nieuwegein, The Netherlands; [email protected] 2 Department of Pulmonology, St. Antonius Hospital, 3435 CM Nieuwegein, The Netherlands; [email protected] (A.E.H.); [email protected] (J.J.M.); [email protected] (R.J.S.) 3 Department of Cardiology, University Medical Center Utrecht, 3584 CM Utrecht, The Netherlands * Correspondence: [email protected]; Tel.: +31-883203000 Abstract: In this review, we discuss the role of transforming growth factor-beta (TGF-β) in the development of pulmonary vascular disease (PVD), both pulmonary arteriovenous malformations (AVM) and pulmonary hypertension (PH), in hereditary hemorrhagic telangiectasia (HHT). HHT or Rendu-Osler-Weber disease is an autosomal dominant genetic disorder with an estimated prevalence of 1 in 5000 persons and characterized by epistaxis, telangiectasia and AVMs in more than 80% of cases, HHT is caused by a mutation in the ENG gene on chromosome 9 encoding for the protein endoglin or activin receptor-like kinase 1 (ACVRL1) gene on chromosome 12 encoding for the protein ALK-1, resulting in HHT type 1 or HHT type 2, respectively. A third disease-causing mutation has been found in the SMAD-4 gene, causing a combination of HHT and juvenile polyposis coli. All Citation: Bofarid, S.; Hosman, A.E.; three genes play a role in the TGF-β signaling pathway that is essential in angiogenesis where it Mager, J.J.; Snijder, R.J.; Post, M.C.
    [Show full text]
  • Mirna Replacement in Aortic Calcification Ying Tang1, †, Tapan A
    MicroRNA profiles in calcified and healthy aorta: therapeutic impact of miR-145 and miR-378 Running title: miRNA replacement in aortic calcification Ying Tang1, †, Tapan A. Shah1, †, ‡, Edward J. Yurkow2, and Melissa B. Rogers1, ‡ 1Rutgers - New Jersey Medical School, Microbiology, Biochemistry, & Molecular Genetics, Newark, NJ 2Rutgers University Molecular Imaging Center (RUMIC), Rutgers University, Piscataway, NJ †Co-first authors ‡Present Address: Advanced Cell Diagnostics, 7707 Gateway Blvd #200, Newark, CA 94560 §To whom should correspondence and reprint request be addressed to: Melissa B. Rogers, Ph.D., Microbiology, Biochemistry & Molecular Genetics, Rutgers - NJ Medical School (NJMS), Center for Cell Signaling, Room F1216, 205 South Orange Ave., Newark, NJ 07103. Email: [email protected], telephone: 973 972 2984 Fig. S1. Experimental Controls. Fig. S2. KEGG (Kyoto Encyclopedia of Genes and Genomes) analyses of differentially expressed miRNAs in male Klotho homozygous mutant mice. Fig. S3. KEGG (Kyoto Encyclopedia of Genes and Genomes) analyses of differentially expressed miRNAs in female Klotho homozygous mutant mice. Fig. S4. Gene Ontology (GO) analyses of differentially expressed miRNAs in male Klotho homozygous mutant mice. Fig. S5. Gene Ontology (GO) analyses of differentially expressed miRNAs in female Klotho homozygous mutant mice. Fig. S6. Interaction network of miRNAs down-regulated in male Klotho homozygotes relative to healthy controls. Fig. S7. Interaction network of miRNAs down-regulated in female Klotho homozygotes relative to healthy controls. Table S1. Klotho wild type and Klotho heterozygous mice are equivalent controls. Table S2. Average miRNA abundance in aorta from Klotho mutant homozygotes relative to healthy control (p<0.05). Table S3. Genes targeted by selected miRNAs that may influence aortic calcification.
    [Show full text]
  • ACVRL1 Signaling Augments Cd8α+ Dendritic Cell Development
    Cutting Edge: ACVRL1 Signaling Augments CD8 α+ Dendritic Cell Development Rohit Verma, Hemant Jaiswal, Kuldeep Singh Chauhan, Monika Kaushik and Prafullakumar Tailor This information is current as of September 29, 2021. J Immunol 2016; 197:1029-1034; Prepublished online 15 July 2016; doi: 10.4049/jimmunol.1501849 http://www.jimmunol.org/content/197/4/1029 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2016/07/14/jimmunol.150184 Material 9.DCSupplemental References This article cites 31 articles, 12 of which you can access for free at: http://www.jimmunol.org/ http://www.jimmunol.org/content/197/4/1029.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 29, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Th eJournal of Cutting Edge Immunology Cutting Edge: ACVRL1 Signaling Augments CD8a+ Dendritic Cell Development Rohit Verma, Hemant Jaiswal, Kuldeep Singh Chauhan, Monika Kaushik, and Prafullakumar Tailor Dendritic cells (DCs) are a collection of different sub- netic proteins [BMPs], growth-differentiation factor, NODAL, types, each of which is characterized by specific surface activins/inhibins, and anti-Mullerian€ hormone) involves com- markers, gene-expression patterns, and distinct func- binationsoftwotypesofreceptors:typeI(alsoknownas tions.
    [Show full text]
  • BMPR2 Inhibits Activin- and BMP-Signaling Via Wild Type ALK2
    bioRxiv preprint doi: https://doi.org/10.1101/222406; this version posted November 22, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 BMPR2 inhibits activin- and BMP-signaling via wild type ALK2 2 3 Oddrun Elise Olsen1,2, Meenu Sankar3, Samah Elsaadi1, Hanne Hella1, Glenn Buene1, Sagar 4 Ramesh Darvekar1, Kristine Misund1,2, Takenobu Katagiri4 and Toril Holien1,2* 5 6 (1) Department of Clinical and Molecular Medicine, NTNU – Norwegian University of 7 Science and Technology, Trondheim, Norway. 8 (2) Clinic of Medicine, St. Olav’s University Hospital, Trondheim, Norway. 9 (3) School of Bioscience, University of Skövde, Skövde, Sweden. 10 (4) Division of Pathophysiology, Research Center for Genomic Medicine, Saitama Medical 11 University, Hidaka-shi, Saitama 350-1241, Japan. 12 13 * Corresponding author 14 E-mail: [email protected] 15 16 17 Running title: BMPR2 inhibits ALK2 activity 18 19 Key words: Bone Morphogenetic Protein, BMPR2, ACVR2A, ACVR2B, Activin, ACVR1 1 bioRxiv preprint doi: https://doi.org/10.1101/222406; this version posted November 22, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Summary Statement 2 The activation of SMAD1/5/8 via endogenous wild type ALK2 by activin A, activin B, and 3 certain BMPs was enhanced when BMPR2 levels were knocked down. 4 5 6 Abstract 7 Activin A is a member of the TGF-β superfamily and activates the transcription factors 8 SMAD2/3 through the ALK4 type 1 receptor.
    [Show full text]
  • 1 ACVR1 Antibodies Exacerbate Heterotopic Ossification In
    bioRxiv preprint doi: https://doi.org/10.1101/2021.07.18.452865; this version posted July 19, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1 Senem Aykul1* Lily Huang1* Lili Wang1 Nanditha Das1 Sandra Reisman1 Yonaton Ray1 Qian Zhang1 Nyanza Rothman1 Kalyan C. Nannuru1 Vishal Kamat1 Susannah Brydges1 Luca Troncone2 Laura Johnsen1 Paul B. Yu2 John Lees-Shepard1 Kevin Schutz3 Andrew J. Murphy1 Aris N. Economides1† Vincent Idone1† Sarah J. Hatsell1† *Indicates equal contribution. †Indicates equal contribution; to whom correspondence should be addressed. [email protected], [email protected], [email protected] 1Regeneron Pharmaceuticals Inc, 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA. 2Department of Medicine, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02114, USA. 3Adimab, 7 Lucent Dr, Lebanon, NH 03766, USA. bioRxiv preprint doi: https://doi.org/10.1101/2021.07.18.452865; this version posted July 19, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 2 Abstract Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disorder whose most debilitating pathology is progressive and cumulative heterotopic ossification (HO) of skeletal muscles, ligaments, tendons, and fascia.
    [Show full text]